None listed
Conditions
Brief summary
The primary objective of this study is to investigate if chlorogenic acid will increase circulating nitric oxide and if these effects are associated vascular benefits.
Interventions
A randomised, controlled cross-over design trial will be conducted to investigate the acute effects of chlorogenic acid on metabolism of nitrogen oxides,as well as blood pressure and endothelial function.
Each participant will complete 2 visits (one treatment at each visit) one week apart in random order. The two treatments are:
1. No chlorogenic acid
2. Chlorogenic acid
Prior to each visit participants will be asked to consume a standard low flavonoid meal for breakfast.
Participants will the
A randomised, controlled cross-over design trial will be conducted to investigate the acute effects of chlorogenic acid on metabolism of nitrogen oxides,as well as blood pressure and endothelial function. Each participant will complete 2 visits (one treatment at each visit) one week apart in random order. The two treatments are: 1. No chlorogenic acid 2. Chlorogenic acid Prior to each visit participants will be asked to consume a standard low flavonoid meal for breakfast. Participants will then attend the School of Medicine and Pharmacology Research Unit at Royal Perth Hospital where they will be provided with 400 mg chlorogenic acid in 200 ml water.
Sponsors
University of Western Australia
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Men and women aged 18 to 65 years
Exclusion criteria
1. Current or recent (<12 months) smoking 2. Body mass index < 18 or > 35 kg/m2, 3. History of cardiovascular or peripheral vascular disease, 4. A systolic blood pressure below 100 or above 160 mmHg 5. A diastolic blood pressure below 50 or above 100 mmHg 6. Diagnosed diabetes, and non-diabetic individuals with 7.Fasting plasma glucose concentrations greater than or equal to 5.5 mmol/L, 8. A psychiatric illness, 9. Other major illnesses such as cancer, 10. Current or recent (within previous 6 months) significant 11. Weight loss or gain (> 6% of body weight), 12. Reported lactating, pregnant or wishing to become pregnant during the study, 13. Alcohol intake > 210 g per wk for women and > 280 g per wk for men, and 14. Inability or unwillingness to consume foods/beverages provided. 15. Unwillingness to stop the use of supplements 24 hours prior to the testing day. 16. Have any health conditions that would affect food metabolism including the following: food allergies, kidney disease, liver disease and/or gastrointestinal diseases (e.g Irritable bowel syndrome, celiac disease, peptic ulcers)
Outcome results
None listed